Accutar Biotechnology
PrivateLast Round
Series C
Apr 7, 2021
Total Funding Raised
$63.15M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Accutar Biotechnology operates in Healthcare & Life Sciences and is based in Cranbury, New Jersey. Its latest recorded funding round was a Series C round in April 2021.
Accutar Biotechnology is a clinical-stage biotechnology company that utilizes an artificial intelligence-empowered platform for drug discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accutar Biotechnology Comparables
Compare Accutar Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SEED Therapeutics | 84% | |
| Celeris Therapeutics | 84% | |
| Genesis Molecular AI | 84% |
For institutional investors. Book with your work email.
Accutar Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 7, 2021 | ||||
| Early Funding | Dec 21, 2020 | ||||
| Series B | Dec 21, 2020 | ||||
| Early Funding | Aug 12, 2019 | ||||
| Series A | Jan 10, 2018 | ||||
Series A | Dec 5, 2017 |
For institutional investors. Book with your work email.
Accutar Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Early Funding, Series C, Series B |
| IDG Capital | Series C, Series A |
| ZhenFund | Seed |
| Primavera Capital Group | Early Funding, Series C |
| Primavera Venture Partners | Series B |
| Yunfeng Capital | Series C |
| CDH Investments | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 99% MoM.
- Jul 25, 2026
Monthly visitors grew 299% MoM, reaching 1.1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 15, 2026
Accutar Biotech Inc. reaches a preclinical development milestone with Cytokinetics in their collaboration to discover and develop novel targeted protein degraders for muscle-related diseases in New Jersey on Oct 15th '26.
- partners_withOct 15, 2026
Accutar Biotech Inc. and Cytokinetics collaborate to discover and develop targeted protein degraders for muscle-related diseases, with Accutar Biotech Inc. achieving a preclinical development milestone in New Jersey on Oct 15th '26.
For institutional investors. Book with your work email.
Accutar Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Accutar Biotechnology's valuation, stock price, and market status.
Is Accutar Biotechnology a public or private company?
Accutar Biotechnology is a private company.
What is the current stock price of Accutar Biotechnology?
Accutar Biotechnology is a private company, so its shares have no public market price. Caplight tracks Accutar Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Accutar Biotechnology worth (valuation)?
Valuation information for Accutar Biotechnology is not publicly available.
Can I buy Accutar Biotechnology stock?
Accutar Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Accutar Biotechnology's last funding round?
Accutar Biotechnology's most recent funding round was Series C on April 7, 2021.
Who are the main investors in Accutar Biotechnology?
Key investors in Accutar Biotechnology include CDH Investments, IDG Capital, Primavera Venture Partners, Yunfeng Capital, 3W Partners Capital.
Will Accutar Biotechnology IPO soon?
No public IPO plans have been announced for Accutar Biotechnology.
How can I track Accutar Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Accutar Biotechnology's shares on secondary markets.